Key result
Targeting renal inflammation, particularly in patients with autoimmune diseases like systemic lupus erythematosus or resistant hypertension, may offer a novel therapeutic approach to improve blood pressure control.
Why the study?
Hypertension remains a global burden, and understanding alternative mechanisms like immune overactivation and renal inflammation is needed to reveal novel therapeutic targets, especially for resistant hypertension.
Targeting renal inflammation may offer a novel therapeutic approach for patients with resistant hypertension.
Renal immune activation may contribute to resistant hypertension; leaves open anti-inflammatory targets pending prospective trials.
Despite extensive research and a plethora of therapeutic options, hypertension continues to be a global burden. Understanding of the pathological roles of known and underexplored cellular and molecular pathways in the development and maintenance of hypertension is critical to advance the field. Immune system overactivation and inflammation in the kidneys are proposed alternative mechanisms of hypertension, and resistant hypertension. Consideration of the pathophysiology of hypertension in chronic inflammatory conditions such as autoimmune diseases, in which patients present with autoimmune-mediated kidney inflammation as well as hypertension, may reveal possible contributors and novel therapeutic targets. In this review, we 1) summarize current therapies used to control blood pressure and their known effects on inflammation; 2) provide evidence on the need to target renal inflammation, specifically, and especially when first-line and combinatory treatment efforts fail; and 3) discuss the efficacy of therapies used to treat autoimmune diseases with a hypertension/renal component. We aim to elucidate the potential of targeting renal inflammation in certain subsets of patients resistant to current therapies.
No takes yet. Share an insight, caveat, or question.
Chaudhari et al. (2022) conducted a review in Hypertension and Renal Inflammation (e.g., Systemic Lupus Erythematosus). Anti-inflammatory therapies targeting renal inflammation was evaluated. Targeting renal inflammation, particularly in patients with autoimmune diseases like systemic lupus erythematosus or resistant hypertension, may offer a novel therapeutic approach to improve blood pressure control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: